Skip to main content

Government News


Clinical courses


Pharma courses

  • Indian government helping hands in rare disease treatment

    The Indian government has taken a dominant step towards treatment of patients suffering from rare diseases. So far in this fiscal year, the government has allocated Rs. 92.84 crore for treatment of rare diseases.

    As per the data available with Indian Council of Medical Research (ICMR), 9,675 patients have been enrolled since November, 2019 on the portal of National Registry for Rare and Other Inherited Disorders (NRROID) out of which 4,408 patients are from centrally governed Hospitals.

  • Biotech StartUps are crucial to Indias future economy

    Union Minister of State (Independent Charge) for Science and Technology, MoS PMO, Department of Atomic Energy and Department of Space and MoS Personnel, Public Grievances and Pensions, Dr Jitendra Singh has said that the Biotech StartUps are crucial to India’s future economy.

  • PCI opposes Jharkhand governments announcement on granting permission to open pharmacies by unqualified people

    The Pharmacy Council of India (PCI) has urged the Jharkhand government to recall its decision of granting permission for opening pharmacies in rural areas without registered pharmacists.

  • CDSCO to publish daily analysis reports of cough syrup for export

    CDSCO to update on a daily basis about batches of cough syrup samples received at each of the central or state drug laboratories. This is to enable work distribution amongst the lab and for release of test reports in a time bound manner by these laboratories.

    There is an ongoing global threat posed by toxic cough syrups, the World Health Organization (WHO) told Reuters. The WHO issued safety alerts last year for Indian-made products found in Gambia and Uzbekistan, and this year in Micronesia and the Marshall Islands.

  • Indian Drugs Controller approves first indigenously developed animal-derived tissue engineering scaffold for healing skin wounds with minimum scarring

    The first indigenously developed tissue engineering scaffold from mammalian organs, an animal-derived Class D Biomedical Device that can rapidly heal skin wounds at low-cost with minimum scarring, has received approval from the Indian Drugs Controller.

  • Government has banned 14 FDCs which has no therapeutics justification

    Government has banned 14 FDCs after recommendations of the Expert Committee which stated that there is no therapeutic justification for these FDCs and the FDCs may involve risk to human beings.

    The Central Government in exercise of the powers conferred by section 26A of the Drugs and Cosmetics act 1940 (23 of 1940) prohibited the manufacture for sale, sale and distribution for human use of 14 drug FDCs (fixed dose combinations).

  • DCA shuts 11 pharma companies in Himachal Pradesh

    The Drug Control Administration (DCA) has stopped 11 pharmaceutical manufacturing firms located in the pharmaceutical hub of Baddi, Barotiwala, Nalagarh, Sirmaur and Kangra districts after significant observations were detected in its functioning during risk-based inspections conducted recently.

    State Drugs Controller Navneet Marwaha said, "In the last two months, 29 firms were inspected in the second phase of the joint inspection by the state DCA and the Central Drugs Standard Control Organisation."

  • Cough syrup testing at government labs mandatory before export

    The Director General of foreign Trade made an amendment in the export policy of cough syrup. Now, it is required to test export samples from government labs before exporting cough syrup.

    As per revised export policy, cough syrup shall be permitted to be exported subject to the export sample being tested and production of certificate of analysis issued by government laboratories.

  • Now CROs require authorisation from Central Licencing Authority

    As per new amendment of New Drugs and Clinical Trials, Clinical Research Organisations cannot conduct any clinical trial or bioavailability studies without permission from Central Licencing Authority.

    As per new amendment, application for registration of Clinical Research Organisation for the purpose of conducting clinical trial or bioavailability or bioequivalence study with the Central Licencing Authority shall be made to the said authority in Form CT-07B.

  • Cabinet approves the Policy for the Medical Devices Sector

    The Union Cabinet, chaired by the Hon'ble Prime Minister Shri Narendra Modi, today approved the National Medical Devices Policy, 2023.

Subscribe to Government News